SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff has focused discussion on its heavy debt, costly financing needs and insider selling, alongside concerns about broader weakness in AI infrastructure stocks. Traders are split between fears of dilution or default and hopes that contracted AI demand, analyst support and buying near recent lows could underpin a recovery.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention amid a steep post-IPO selloff, with traders pointing to upcoming share unlocks, reported insider selling, and a TD Cowen price-target cut as sources of pressure. The debate is whether the decline is temporary supply and AI-sector weakness or reflects deeper concerns about customer concentration, growth, and valuation; some traders see an oversold opportunity while others expect further downside.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealths quarterly earnings beat and raised full-year outlook, alongside improved medical-cost trends, are driving attention. Bulls view the results as evidence of a turnaround and welcome the rebound, while skeptics question whether the improvement will last and point to the stocks volatile reaction despite the strong report.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is drawing attention amid a sharp, prolonged pullback and a wider semiconductor selloff, with traders debating whether concerns about AI spending, financing, and returns signal a broader downturn. Many blame CEO Hock Tans comments likening AI investing to gambling for worsening sentiment, while others view the selloff as a buying opportunity.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention after a sharp selloff across AI-infrastructure stocks, fueled by concerns about neocloud financing, debt and whether heavy AI spending will generate sufficient returns. Traders are split on whether the rebound from oversold levels signals a recovery or a temporary bounce, with some arguing Nebius is better positioned than more debt-heavy peers.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is drawing attention amid a volatile rebound after a broad AI and semiconductor selloff, as traders debate whether heavy AI infrastructure spending and debt financing can generate adequate returns. Bulls point to continued chip demand and company announcements, while skeptics warn of an AI spending bubble and further sector weakness.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Ciphers steep selloff is dominated by concerns that its convertible-note financing and added shares will dilute investors, alongside weakness across AI and data-center infrastructure stocks. Bears question management, debt and execution, while some holders see the decline as an oversold pullback and remain bullish on the companys longer-term AI hosting opportunity.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers recent climb toward a 52-week high and a key round-number resistance level is driving discussion, with traders highlighting bullish chart momentum and a defensive rotation into pharma. Others question whether the move can hold, pointing to resistance and the absence of a single clear near-term catalyst.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is under pressure at new lows, with traders linking the decline to Trumps falling approval and approaching midterms. Discussion is largely bearish, though a few see a speculative buying opportunity, while others point to concerns about the companys media-business fundamentals.

Aventus Network

Aventuss disclosure that an attacker exploited a code vulnerability to mint and sell AVT has fueled attention to the tokens sharp swings in thin markets; the team says the exploit is patched and the attacker has exited. Traders are split between hoping for a low-float rebound and worrying about concentrated holdings, supply changes, and persistent selling pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AstraZenecas $2 billion strategic investment in Summit Therapeutics and expanded cancer-drug collaboration is a major discussion point, with traders viewing the deal as a vote of confidence in Summits oncology program. Other posts point to AstraZenecas AI drug-discovery partnership with insitro and debate the companys pipeline and recent trial setbacks.

The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology

AstraZeneca, Roche, Puma Biotechnology and Olema Oncology offer breast cancer treatment opportunities, with drug sales growth, pipeline advances and clinical milestones shaping prospects.

SLS Stock Logs Worst Week In Over A Month: Retail Bulls Bet ASH Embargo Is Keeping Regal Results Under Wraps 

Equity

Sellas’s 600-square-foot ASH booth also fueled speculation about a potential clinical update.

Nurse Deemed 'Not Disabled Enough' For Payout After COVID Jab Paralysis

Nurse Deemed 'Not Disabled Enough' For Payout After COVID Jab Paralysis

 Authored by Steve Watson via Modernity.news,

An NHS nurse in the UK has been denied compensation despite being permanently damaged by a COVID vaccine during a trial.

Marie-Claire Hoyle, who volunteered for the...

Stocktwits Biotech Dealmaker: Gilead, AstraZeneca And Roche Chase Pipeline Expansion Over Buyouts

Deals for AI discovery platforms and differentiated experimental candidates for obesity and solid tumors dominated the week.


4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month

AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.

Astrazeneca (AZN) Rises Higher Than Market: Key Facts

Astrazeneca (AZN) closed the most recent trading day at $166.68, moving +2.87% from the previous trading session.

Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth?

Gilead Sciences expands its oncology pipeline through a Vir Biotechnology deal worth up to $1.74 billion in additional milestones, targeting three novel cancer therapies.

AstraZeneca, insitro Strike AI Drug Discovery – What Investors Need To Know 

AstraZeneca will use insitro’s AI platform to identify potential drug targets for MASH and cardiomyopathies, drawing on its own clinical development and regulatory expertise to advance selected programs.


The Zacks Analyst Blog Highlights Mastercard, AstraZeneca and Sandisk

Mastercard, AstraZeneca and Sandisk face distinct opportunities and risks, from payment competition and drug pipeline growth to surging AI-driven storage demand.

Top Research Reports for Mastercard, AstraZeneca & Sandisk

Mastercard's payment growth, AstraZeneca's drug pipeline and Sandisk's AI-driven SSD demand headline today's top research reports, revealing key growth drivers and risks for investors.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

Neutral Sentiment

<ul class="summary-bullets"><li>Some retail bulls speculated that an ASH embargo could be keeping Regal trial results under wraps.</li><li>Regal requires 80 deaths to trigger final analysis and Sellas’s last disclosed count was 78.</li><li>ASH’s regular abstracts are released on Nov.4 and late-breaking abstracts on Dec.7.</li></ul>Shares of Sellas Life Sciences (SLS) shares logged their worst week in over a month as some retail investors speculated that its key Regal trial results could be under wraps ahead of a major hematology conference.<a href="https://stocktwits.com/symbol/SLS">SLS stock</a> closed Friday at $9.98 after tumbling nearly 12%, extending its losing streak to three sessions. Shares also ended the week 14% lower, logging their worst week in over a month.<h2 class="st-heading-2">ASH Plans Put Regal In The Spotlight</h2>The American Society of Hematology’s (ASH) annual meeting in New Orleans has now become a focus for investors looking for clues about Sellas’s next clinical update. The company is listed at Booth 138, a 600-square-foot space beside the poster area in Hall G. Eli Lilly, Takeda, Genentech and AstraZeneca also have exhibits in the hall, placing Sellas among major pharma companies at the blood-disease conference.&nbsp;The attention comes as Sellas approaches a key milestone for Galinpepimut-S (GPS), its immunotherapy targeting the WT1 protein. Regal is testing GPS in acute myeloid leukemia (AML) patients who achieved a second remission following salvage treatment.The study requires 80 deaths to trigger its final analysis. Sellas’s last disclosed count was 78, and the company has said it will announce when the threshold is reached. Database lock and blinded review must then precede statistical analysis, unblinding and topline disclosure.&nbsp;<h2 class="st-heading-2">SLS Bulls Pin Hopes On An ASH Reveal</h2>On Stocktwits, sentiment for SLS jumped to “bullish” from ‘neutral’ levels a week ago amid ‘high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/sls_ss_816ac15f97.png" alt="sls ss.png" width="635" height="350"><figcaption>SLS sentiment and message volume as of October 18 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/biospeculator/message/666634177">said</a> they believed the company’s silence reflected ASH embargo restrictions and suggested that Regal results could emerge with the conference’s regular abstract release. The user treated the booth commitment as a sign of confidence, asking, “Do you believe SLS would secure a 600sq ft booth at the largest cancer conference of the year in order to release bad results? I do not.”Another user&nbsp;<a href="https://stocktwits.com/Hannibal_Smith/message/666768152">questioned</a> whether Sellas could prepare a late-breaking submission if Regal had not yet reached its final event threshold: “If 80 event didn’t happen yet, it’s highly unlikely they will be in time to submit Topline for late breaking abstracts.”&nbsp;A separate user&nbsp;<a href="https://stocktwits.com/BiotechSwings/message/666802413">played down</a> the significance of the booth, noting that hundreds of companies exhibit at ASH and adding that the 80th Regal event remained the milestone to watch.ASH’s policy states that regular abstract data remain under embargo until Nov.4, while late-breaking abstracts are restricted until Dec.7. Additional findings generally remain embargoed until the relevant presentation or poster session. Companies can request exceptions to release limited topline data when required by securities laws.<h2 class="st-heading-2">SLS009 Adds A Second Data Watch</h2>Sellas is also advancing SLS009, a selective CDK9 inhibitor, with topline data expected in the fourth quarter from an 80-patient Phase 2 trial in newly diagnosed AML. The study includes patients whose disease becomes resistant early to Azacitidine and Venetoclax.&nbsp;The company is exploring the drug’s potential beyond leukemia as well. In a lab pancreatic-cancer model resistant to Daraxonrasib, SLS009 produced 17.9% apoptosis, or programmed cell death, compared with 2.8% for Daraxonrasib alone. Combining the treatments raised apoptosis to 36.5% and necrosis to 30.6%.SLS stock has jumped 165% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stocktwits-pharma-pulse-moderna-merck-cancer-vaccine-spotlight-kidney-cancer-ms-data/cZx8JvJRBtx">Stocktwits Pharma Pulse: Moderna-Merck Cancer Vaccine Grabs Spotlight As Kidney-Cancer And MS Data Pour In&nbsp;</a>

In this photo illustration, the SELLAS Life Sciences Group logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

SLS Stock Logs Worst Week In Over A Month: Retail Bulls Bet ASH Embargo Is Keeping Regal Results Under Wraps

AstraZeneca PLC

Lilly(Eli) & Co

SELLAS Life Sciences Group Inc

SPDR S&P Biotech ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$163.95
Prev Close	$165.41
Open	$164.51
Dividend Yield	1.68%
50-Day Moving Average	$162.18
Beta	0.34
Avg. Volume	2.98M
PE Ratio	24.33

52-Week High	$212.71
52-Week Low	$153.41
Market Capitalization	$254.27B
EPS (Annual)	$6.60
Price to Book	5.06
Revenue Per Employee	$611,227.89

Feed

News

Sentiment

Earnings

Fundamentals

Info

AZN Fundamentals